NEURENTIS PLC

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

MHA

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on a going concern basis. The company currently has no ongoing trading commitments and meets its liabilities as they fall due from shareholder funding which the shareholders have confirmed they will continue to provide. The directors expect to raise substantial funds in due course to finance the growth and development of the company in line with their business plans, and will ensure that this will be sufficient to meet its commitments.”

Group structure

1. NEURENTIS PLC · parent
   1. Neurentis (UK) Limited (Formerly Akesi Health Limited) 100% · UK · pharmaceutical
   2. Neurentis BV 100% · Belgium

Significant events

• “In 2024, Neurentis made a strategic breakthrough that significantly accelerated the development trajectory of our lead asset, the Quivara™™ patch for treatment-resistant depression (TRD). We entered into a confidential collaboration with a major U.S. pharmaceutical company, under which we plan to conduct a pivotal Phase 3 trial using our proprietary Quivara™™ brand.”
• “We signed an agreement with Netellis, a U.S.-based company at the forefront of artificial intelligence in drug discovery.”
• “We strengthened our leadership team during the reporting period with the addition of two Senior Vice Presidents, a New Product Development Manager and a seasoned Regulatory Advisor.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

2

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +8,594.2%

  £428 → £37,211

• Net assets

  -1.8%

  £2,122,958 → £2,085,489

• Employees

  0%

  3 → 3

• Profit before tax

  -38%

  -£27,142 → -£37,469

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers